ECOR (electroCore) Short-term investments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ECOR electroCore Inc ECOR
76 GF Score
Price $9.73
GF Value $8.64
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is electroCore Short-term investments?

Short-term investments only applies to insurance companies.

ECOR
76GF Score
electroCore Inc ECOR
Short-term investments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is electroCore (ECOR) Overvalued in 2026?

Based on GuruFocus' analysis, electroCore stock appears to be overvalued. The current stock price of $9.73 is trading 12.6% above its estimated GF Value™ of $8.64. GuruFocus considers electroCore to be Modestly Overvalued.

Key valuation signals for ECOR:

  • Short-term investments:
  • GF Value™: $8.64 vs. price of $9.73 (12.6% above fair value)
  • GF Score™: 76/100 with 5 warning signs

No single metric tells the full story. See the ECOR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


electroCore Business Description

Other Exchanges 43E0:Germany
Address 200 Forge Way, Suite 205, Rockaway, NJ, USA, 07866
electroCore Inc is a bioelectronic technology company whose mission is to improve health and quality of life through non-invasive bioelectronic technologies. Its two commercial products are gammaCore non-invasive vagus nerve stimulation, or nVNS, and Quell Fibromyalgia, or Quell. It also sells Truvaga and TAC-STIM products, which are handheld, personal-use consumer products developed to promote general wellness and human performance. It operates in one segment: Bioelectronic Innovations. Geographically, it operates in the United States, the United Kingdom, Japan, and Other.
76GF Score

Get the complete analysis for ECOR

Short-term investments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.73
Price
$8.64
GF Value